Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs

被引:236
作者
Katlama, Christine [1 ]
Deeks, Steven G. [2 ]
Autran, Brigitte [3 ]
Martinez-Picado, Javier [4 ,5 ]
van Lunzen, Jan [6 ]
Rouzioux, Christine [7 ]
Miller, Michael [8 ]
Vella, Stefano [9 ]
Schmitz, Joern E. [10 ]
Ahlers, Jeffrey [14 ]
Richman, Douglas D. [11 ,12 ,13 ]
Sekaly, Rafick P. [14 ]
机构
[1] Univ Paris 06, Dept Infect Dis, Pitie Salpetriere Hosp, Paris, France
[2] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[3] Univ Paris 06, Lab Immun & Infect, Hosp Pitie Salpetriere, Paris, France
[4] ICREA, AIDS Res Inst IrsiCaixa, Badalona, Spain
[5] Univ Autonoma Barcelona, Badalona, Spain
[6] Univ Med Ctr Hamburg Eppendorf, Infect Dis Unit, Hamburg, Germany
[7] Paris Descartes Univ, Necker Hosp, Dept Virol, Paris, France
[8] Merck Res Labs, Dept West Point Discovery Chem, West Point, PA USA
[9] Super Hlth Inst, Dept Pharmacol & Therapeut Res, Rome, Italy
[10] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Ctr Virol & Vaccine Res, Boston, MA 02215 USA
[11] Univ Calif San Diego, VA San Diego Healthcare Syst, San Diego, CA 92103 USA
[12] Univ Calif San Diego, Dept Pathol, Ctr AIDS Res, San Diego, CA 92103 USA
[13] Univ Calif San Diego, Dept Med, Ctr AIDS Res, San Diego, CA 92103 USA
[14] Vaccine & Gene Therapy Inst Florida, Port St Lucie, FL 34987 USA
基金
美国国家卫生研究院;
关键词
ACTIVE-ANTIRETROVIRAL-THERAPY; CD4(+) T-CELLS; IMMUNODEFICIENCY-VIRUS TYPE-1; CHRONIC VIRAL-INFECTION; NF-KAPPA-B; IMMUNE ACTIVATION; LATENT HIV-1; LYMPH-NODES; VALPROIC ACID; MICROBIAL TRANSLOCATION;
D O I
10.1016/S0140-6736(13)60104-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Antiretroviral therapy for HIV infection needs lifelong access and strict adherence to regimens that are both expensive and associated with toxic effects. A curative intervention will be needed to fully stop the epidemic. The failure to eradicate HIV infection during long-term antiretroviral therapy shows the intrinsic stability of the viral genome in latently infected CD4T cells and other cells, and possibly a sustained low-level viral replication. Heterogeneity in latently infected cell populations and homoeostatic proliferation of infected cells might affect the dynamics of virus production and persistence. Despite potent antiretroviral therapy, chronic immune activation, inflammation, and immune dysfunction persist, and are likely to have important effects on the size and distribution of the viral reservoir. The inability of the immune system to recognise cells harbouring latent virus and to eliminate cells actively producing virus is the biggest challenge to finding a cure. We look at new approaches to unravelling the complex virus-host interactions that lead to persistent infection and latency, and discuss the rationale for combination of novel treatment strategies with available antiretroviral treatment options to cure HIV.
引用
收藏
页码:2109 / 2117
页数:9
相关论文
共 113 条
  • [61] Reduction of Immune Activation with Chloroquine Therapy during Chronic HIV Infection
    Murray, Shannon M.
    Down, Carrie M.
    Boulware, David R.
    Stauffer, William M.
    Cavert, Winston P.
    Schacker, Timothy W.
    Brenchley, Jason M.
    Douek, Daniel C.
    [J]. JOURNAL OF VIROLOGY, 2010, 84 (22) : 12082 - 12086
  • [62] A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity
    Mussolino, Claudio
    Morbitzer, Robert
    Luetge, Fabienne
    Dannemann, Nadine
    Lahaye, Thomas
    Cathomen, Toni
    [J]. NUCLEIC ACIDS RESEARCH, 2011, 39 (21) : 9283 - 9293
  • [63] Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
    Palmer, Sarah
    Malclarelli, Frank
    Wiegand, Ann
    Bernstein, Barry
    Hanna, George J.
    Brun, Scott C.
    Kempf, Dale J.
    Mellors, John W.
    Coffin, John M.
    King, Martin S.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (10) : 3879 - 3884
  • [64] Effects of Hydroxychloroquine on Immune Activation and Disease Progression Among HIV-Infected Patients Not Receiving Antiretroviral Therapy A Randomized Controlled Trial
    Paton, Nicholas I.
    Goodall, Ruth L.
    Dunn, David T.
    Franzen, Samuel
    Collaco-Moraes, Yolanda
    Gazzard, Brian G.
    Williams, Ian G.
    Fisher, Martin J.
    Winston, Alan
    Fox, Julie
    Orkin, Chloe
    Herieka, Elbushra A.
    Ainsworth, Jonathan G.
    Post, Frank A.
    Wansbrough-Jones, Mark
    Kelleher, Peter
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 308 (04): : 353 - 361
  • [65] Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation
    Patsoukis, Nikolaos
    Brown, Julia
    Petkova, Victoria
    Liu, Fang
    Li, Lequn
    Boussiotis, Vassiliki A.
    [J]. SCIENCE SIGNALING, 2012, 5 (230)
  • [66] CD160 and PD-1 Co-Expression on HIV-Specific CD8 T Cells Defines a Subset with Advanced Dysfunction
    Peretz, Yoav
    He, Zhong
    Shi, Yu
    Yassine-Diab, Bader
    Goulet, Jean-Philippe
    Bordi, Rebeka
    Filali-Mouhim, Ali
    Loubert, Jean-Baptiste
    El-Far, Mohamed
    Dupuy, Franck P.
    Boulassel, Mohamed Rachid
    Tremblay, Cecile
    Routy, Jean-Pierre
    Bernard, Nicole
    Balderas, Robert
    Haddad, Elias K.
    Sekaly, Rafick-Pierre
    [J]. PLOS PATHOGENS, 2012, 8 (08)
  • [67] Bryostatin-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency
    Perez, Moises
    Garcia de Vinuesa, Amaya
    Sanchez-Duffhues, Gonzalo
    Marquez, Nieves
    Luz Bellido, M.
    Angeles Munoz-Fernandez, M.
    Moreno, Santiago
    Castor, Trevor P.
    Calzado, Marco A.
    Munoz, Eduardo
    [J]. CURRENT HIV RESEARCH, 2010, 8 (06) : 418 - 429
  • [68] The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention
    Peters, Jeffrey M.
    Shah, Yatrik M.
    Gonzalez, Frank J.
    [J]. NATURE REVIEWS CANCER, 2012, 12 (03) : 181 - 195
  • [69] An Exploratory Trial of Cyclooxygenase Type 2 Inhibitor in HIV-1 Infection: Downregulated Immune Activation and Improved T Cell-Dependent Vaccine Responses
    Pettersen, Frank O.
    Torheim, Eirik A.
    Dahm, Anders E. A.
    Aaberge, Ingeborg S.
    Lind, Andreas
    Holm, Malin
    Aandahl, Einar M.
    Sandset, Per M.
    Tasken, Kjetil
    Kvale, Dag
    [J]. JOURNAL OF VIROLOGY, 2011, 85 (13) : 6557 - 6566
  • [70] Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders
    Piconi, Stefania
    Parisotto, Serena
    Rizzardini, Giuliano
    Passerini, Simone
    Terzi, Roberta
    Argenteri, Barbara
    Meraviglia, Paola
    Capetti, Amedeo
    Biasin, Mara
    Trabattoni, Daria
    Clerici, Mario
    [J]. BLOOD, 2011, 118 (12) : 3263 - 3272